Jacobs Levy Equity Management, Inc Cytom X Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,524,076 shares of CTMX stock, worth $1.52 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,524,076

Previous 1,507,717 1.09%

Holding current value

$1.52 Million

Previous $1.84 Million 2.23%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.12 - $1.51 $18,322 - $24,702	16,359 Added 1.09%	1,524,076 $1.8 Million
Q2 2024 Aug 14, 2024	BUY	$1.21 - $5.13 $1.18 Million - $5.02 Million	977,782 Added 184.51%	1,507,717 $1.84 Million
Q1 2024 May 15, 2024	SELL	$1.41 - $2.74 $368,695 - $716,471	-261,486 Reduced 33.04%	529,935 $1.16 Million
Q4 2023 Feb 14, 2024	SELL	$1.07 - $1.55 $278,931 - $404,060	-260,684 Reduced 24.78%	791,421 $1.23 Million
Q3 2023 Nov 16, 2023	SELL	$1.26 - $1.87 $717,323 - $1.06 Million	-569,304 Reduced 35.11%	1,052,105 $1.36 Million
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $380,667 - $518,355	-269,977 Reduced 14.27%	1,621,409 $2.79 Million
Q1 2023 May 15, 2023	BUY	$1.48 - $2.88 $1.82 Million - $3.54 Million	1,229,494 Added 185.75%	1,891,386 $2.86 Million
Q4 2022 Feb 14, 2023	SELL	$1.19 - $1.91 $514,586 - $825,933	-432,426 Reduced 39.52%	661,892 $1.06 Million
Q3 2022 Nov 15, 2022	BUY	$1.23 - $1.97 $243,378 - $389,801	197,869 Added 22.07%	1,094,318 $1.59 Million
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $273,351 - $516,330	-178,661 Reduced 16.62%	896,449 $1.64 Million
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $437,348 - $766,588	-163,801 Reduced 13.22%	1,075,110 $2.87 Million
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $600,465 - $1.15 Million	-155,159 Reduced 11.13%	1,238,911 $5.36 Million
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $85,523 - $127,294	-19,797 Reduced 1.4%	1,394,070 $7.1 Million
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $5.17 Million - $8.09 Million	816,469 Added 136.67%	1,413,867 $8.95 Million
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $45,025 - $61,398	-6,822 Reduced 1.13%	597,398 $4.62 Million
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $67,947 - $82,965	-10,502 Reduced 1.71%	604,220 $3.96 Million
Q3 2020 Nov 16, 2020	BUY	$6.55 - $8.83 $1.25 Million - $1.69 Million	191,180 Added 45.14%	614,722 $4.09 Million
Q2 2020 Aug 17, 2020	BUY	$7.4 - $14.64 $1.34 Million - $2.64 Million	180,530 Added 74.29%	423,542 $3.53 Million
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $79,250 - $188,795	21,953 Added 9.93%	243,012 $1.86 Million
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $710,399 - $1.22 Million	137,408 Added 164.26%	221,059 $1.84 Million
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $77,490 - $128,625	10,500 Added 14.35%	83,651 $617,000
Q2 2019 Aug 13, 2019	BUY	$9.35 - $11.41 $21,972 - $26,813	2,350 Added 3.32%	73,151 $821,000
Q1 2019 May 14, 2019	BUY	$9.5 - $19.16 $375,250 - $756,820	39,500 Added 126.19%	70,801 $761,000
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $55,563 - $81,342	-3,080 Reduced 8.96%	31,301 $579,000
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $230,476 - $319,950	10,780 Added 45.68%	34,381 $786,000
Q1 2018 May 15, 2018	SELL	$21.76 - $34.22 $176,256 - $277,182	-8,100 Reduced 25.55%	23,601 $671,000
Q4 2017 Feb 13, 2018	BUY	$19.0 - $23.09 $369,569 - $449,123	19,451 Added 158.78%	31,701 $669,000
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $165,742 - $222,582	12,250	12,250 $223,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.4M

Call Options Held

112K

Put Options Held

8.3K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Cytom X Therapeutics, Inc. Transaction History